FindTrial
Sign In

From Blood to Saliva: A New, Painless Way to Track Diabetes by evaluating salivary glucose and amylase.

Assessing the role of Salivary Glucose and Amylase as Non-Invasive Biomarkers for monitoring Diabetes Mellitus - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/102336
Enrollment
108
Registered
2026-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E70-E88- Metabolic disorders

Interventions

Control Intervention1: NIL: NIL

Sponsors

JNMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Participants/patients giving written informed consent. 2)Adult healthy (non diabetic) participants -age and sex matched (Group A) 3)Adult patients suffering from diabetes under control (Group B) 4)Adult patients suffering from uncontrolled diabetes - (group C)

Exclusion criteria

Exclusion criteria: Patients having severe diabetic complications, other systemic illness and those who will be under medication for other diseases, will be excluded from this study

Design outcomes

Primary

MeasureTime frame
To establish the role of salivary glucose and alpha amylase as a biomarker in diagnosing and monitoring patients with diabetes thereby making a very easy way of monitoring diabetic patients and thereby helping the diabetic patients non invasive method of monitoring blood glucose.Timepoint: 24 hours—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactMuskaan Shah

Datta Meghe Institute of Medical Science and research

sunitavagha@gmail.com9860244638

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026